Wall Street Zen downgrades Canopy Growth stock to Sell

Published on 10/20/2026 at 22:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue grew 13.00 percent in first-quarter 2027. Canopy Growth stock stands at EUR 0.64 on October 20, 2026, down 0.47 percent versus Tradegate close.

Analyst view and key dates

Wall Street Zen cut Canopy Growth from hold to sell on October 17, 2026.
First-quarter fiscal 2027 revenue increased 13.00 percent, according to the company.
Canopy Growth stock stood at EUR 0.64 at Lang & Schwarz on October 20, 2026, down 0.47 percent versus the Tradegate close.
Second-quarter fiscal 2027 results are scheduled for November 6, 2026.

CGC, CA1380357048, Illustration mit AI erstellt.

Canopy Growth Corporation (ISIN CA1380357048) faced a new sell rating from Wall Street Zen on October 17, 2026. MarketBeat reported that the firm downgraded Canopy Growth from hold to sell, while the broader consensus remained Hold. Canopy Growth stock stood at EUR 0.64 at Lang & Schwarz on October 20, 2026 at 9:59 p.m. CEST, down 0.47 percent versus the Tradegate close of October 19, 2026.

Revenue growth sets the operating backdrop

Canopy Growth reported net revenue growth of 13.00 percent in the first quarter of fiscal 2027, according to its investor-relations page dated August 7, 2026. Canada medical cannabis revenue increased 22.00 percent, while international cannabis revenue rose 10.00 percent in the same period. Those figures put the rating change against a business that is still expanding in selected markets.

EU certification broadens the market story

Canopy Growth received new European Union Good Manufacturing Practices certification for its Smiths Falls facility, with the certification issued by the Tubingen Regional Council on October 8, 2026. Newsweed reported on October 19, 2026 that the approval covers capsules, oral solutions and dried cannabis flowers for European markets. The company generated USD 9.60 million in international cannabis revenue in the first quarter of fiscal 2027, versus USD 8.80 million a year earlier.

Valuation and the next report date

Barron's listed an average price target of USD 1.58 from eight ratings on October 8, 2026, against a quoted price of USD 0.8765 at that time. The same page listed the next results date as November 6, 2026. MarketBeat reported a market capitalization of USD 320.4 million and a price-to-earnings ratio of minus 1.58 on October 17, 2026.

What does the next report need to show?

The November 6, 2026 report will provide the next dated test of whether the 13.00 percent revenue increase is translating into narrower losses. The company reported adjusted earnings per share of minus USD 0.02 for the latest quarter, compared with a consensus loss of USD 0.04, while revenue reached USD 142.62 million against an estimate of USD 58.21 million, according to MarketBeat.

Canopy Growth stock remains below recent highs

The current euro quote is below the Tradegate close used for the daily comparison, while the Nasdaq listing provides the companys primary market context in U.S. dollars. The combination of a recent rating downgrade, expanding international revenue and the November reporting date gives investors three concrete markers for the next update. Canopy Growth stock was trading at EUR 0.64 at Lang & Schwarz on October 20, 2026 at 9:59 p.m. CEST, down 0.47 percent versus the Tradegate close of October 19, 2026 (EUR 0.64). The further course of trading is shown by the continuously updated real-time quote of Canopy Growth stock.